Detailed Information

Cited 0 time in webofscience Cited 16 time in scopus
Metadata Downloads

Multicenter retrospective analysis of the effectiveness and safety of rituximab in Korean patients with refractory systemic lupus erythematosusopen access

Authors
Bang, S.-Y.Lee, C.K.Kang, Y.M.Kim, H.-A.Suh, C.-H.Chung, W.T.Park, Y.-B.Choe, J.-Y.Kim, T.-J.Park, Y.-W.Yoo, D.-H.Bae, S.-C.Lee, H.-S.
Issue Date
Dec-2012
Citation
Autoimmune Diseases, v.1, no.1, pp.1 - 7
Indexed
SCOPUS
Journal Title
Autoimmune Diseases
Volume
1
Number
1
Start Page
1
End Page
7
URI
https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/27416
DOI
10.1155/2012/565039
ISSN
2090-0422
Abstract
Objective. Although two recent randomized placebo-controlled trials of rituximab (RTX) failed to demonstrate efficacy in systemic lupus erythematosus (SLE), clinicians continue to use off-label RTX for cases refractory to current treatments. We evaluated the effectiveness and safety of rituximab for patients with refractory SLE in Korea. Methods. We retrospectively analyzed multicenter patients treated with RTX in Korea. Results. 39 SLE patients treated with RTX were included in the following manner: lupus nephritis 43.6%, hematologic 33.3%, arthritis 7.8%, myositis 7.8%, and others 7.7%. All patients had responded poorly to at least one conventional immunosuppressive agent (mean 2.5 ± 1.1, cyclophosphamide 43.6%, mycophenolate mofetil 48.7%, and other drugs) before RTX. Clinical improvements (complete or partial remission) occurred in patients with renal disease, hematologic disease, arthritis, myositis, and other manifestations at 6 months after RTX. The SLEDAI score was significantly decreased from 10.8 ± 7.1 at baseline to 6.7 ± 4.0 at 6 months, 6.2 ± 4.1 at 12 months, and 5.5 ± 3.6 at 24 months after RTX (P < 0.05). Among 28 clinical responders, 4 patients experienced a relapse of disease at 25 ± 4 months. Infections were noted in 3 patients (7.7%). Conclusion. RTX could be an effective and relatively safe therapeutic option in patients with severe refractory SLE until novel B-cell depletion therapy is available. © 2012 So-Young Bang et al.
Files in This Item
Go to Link
Appears in
Collections
서울 의과대학 > 서울 내과학교실 > 1. Journal Articles

qrcode

Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.

Related Researcher

Researcher Lee, Hye Soon photo

Lee, Hye Soon
COLLEGE OF MEDICINE (DEPARTMENT OF INTERNAL MEDICINE)
Read more

Altmetrics

Total Views & Downloads

BROWSE